Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy

Journal of Clinical Oncology

Volumn 14, Issue 1, 1996, Pages 268-276

  Pecherstorfer, M ^a   Herrmann, Z ^a   Body, J J ^a   Manegold, C ^a   Degardin, M ^a   Clemens, M R ^a   Thurlimann B ^a   Tubiana Hulin, M ^a   Steinhauer, E U ^a   van Eijkeren, M ^a   Huss, H J ^a   Thiebaud D ^a  

^a WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

IBANDRONIC ACID;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BRAIN TOXICITY; CARDIOTOXICITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FLUID THERAPY; GASTROINTESTINAL TOXICITY; HUMAN; HYPERCALCEMIA; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT PLANNING;

EID: 9044238068     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.1.268     Document Type: Article

References (39)

1. Mundy GR: Calcium Homeostasis: Hypercalcemia and Hypocalcemia. London, United Kingdom, Martin Dunitz, 1990, pp 69-100
2. Bonjour JP, Philippe J, Guelpa G, et al: Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate. Bone 9:123-130, 1988
3. Mundy GR: Hypercalcemia of malignancy revisited. J Clin Invest 82:1-6, 1988
4. Pecherstorfer M, Zimmer-Roth I, Schilling T, et al: The diagnostic value of urinary pyridinium crosslinks of collagen, serum total alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 80:97-103, 1995
5. Pfeilschifter J: Cytokines as mediators of hypercalcemia of malignancy, in Raue F (ed): Recent Results in Cancer Research, vol 137. Hypercalcemia of Malignancy. Berlin, Germany, Springer Verlag, 1994, pp 1-19
6. Warrell RP: Metabolic emergencies, in DeVita VT Jr. Hellmann S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 4). Philadelphia, PA, Lippincott, 1993, pp 2128-2134
7. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MML, et al: Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27-39, 1986
8. Flanagan AM, Chambers TJ: Dichloromethylenbisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclasts that resorb C12MBP coated bone. Bone Miner 6:33-43, 1989
9. Sato M, Grasser W, Endo N, et al: Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast structure. J Clin Invest 88:2095-2105, 1991
10. Body JJ, Delmas PD: Urinary pyridinium crosslinks as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 74:471-475, 1992
11. Pecherstorfer M, Seibel MJ, Zimmer-Roth I, et al: Effect of bisphosphonate therapy on urinary pyridinium crosslinks in tumor associated hypercalcemia. Proc Am Soc Clin Oncol 12:112, 1993 (abstr 248)
12. Buchs B, Rizzoli R, Bonjour JP: Evaluation of bone resorption and renal tubular reabsorption of calcium and phosphate in malignant and nonmalignant hypercalcemia. Bone 12:47-56, 1991
13. Harinck HIJ, Bijvoet OLM, Platingh AST, et al: Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 82:1133-1142, 1987
14. Thiébaud D, Jaeger P, Burckhardt P: Response to treatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone. J Bone Miner Res 5:221-226, 1990
15. Body JJ, Dumon JC, Thirion M, et al: Circulating PTHrP concentrations in tumor-induced hypercalcemia: Influence on the response to bisphosphonates and changes after therapy. J Bone Miner Res 8:701-706, 1993
16. Gurney H, Grill V, Martin TJ: Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcemia. Lancet 341:1611-1613, 1993
17. Pecherstorfer M, Schilling T, Blind E, et al: Parathyroid hormone-related protein and life expectancy in hypercalcemic cancer patients. J Clin Endocrinol Metab 78:1268-1270, 1994
18. Wimalawansa SJ: Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 73:2223-2230, 1994
19. Mühlbauer RC, Bauss F, Schenk R, et al: BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res 6:1003-1011, 1991
20. Wüster C, Schöter KH, Thiébaud D, et al: Methylpentylaminopropylidenebisphosphonate (BM 21.0955): A new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia. Bone Mineral 22:77-85, 1993
21. Portale AA: Blood calcium, phosphorus and magnesium, in Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Richmond, VA, William Byrd, 1990, pp 62-64
22. Black D, Duncan A, Robins SP: Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high-performance liquid chromatography. Anal Biochem 169:197-203, 1988
23. Robins SP, Stewart P, Astbury C, et al: Measurement of the crosslink compound, pyridinoline, in urine as an index of collagen degradation. Ann Rheum Dis 45:969-973, 1986
24. Walton RJ, Bijvoet OLM: Nomogram for the derivation of renal threshold phosphate concentration. Lancet 2:309-310, 1975
25. Colett D: Modelling Binary Data. London, United Kingdom, Chapman and Hall, 1991
26. O'Rourke NP, McCloskey EV, Vasikaran S, et al: Effective treatment of malignant hypercalcemia with a single intravenous infusion of clodronate. Br J Cancer 67:560-563, 1994
27. Thürlimann B, Waldburger R, Senn HJ, et al: Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: A prospective randomized crossover trial. Ann Oncol 3:619-622, 1992
28. Gucalp R, Ritch P, Wiernik PH, et al: Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 10:134-142, 1992
29. Body JJ, Dumon JC: Treatment of tumour-induced hypercalcemia with the bisphosphonate pamidronate: Dose-response relationship and influence of tumour type. Ann Oncol 5:359-363, 1994
30. Thiébaud D, Jaeger PH, Jacquet AF, et al: Dose-response in the treatment of hypercalcemia of malignancy by a single infusion of the bisphosphonate AHPrBP. J Clin Oncol 6:762-768, 1988
31. Nussbaum SR, Warrell RP, Rude R, et al: Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia. J Clin Oncol 11:1618-1623, 1993
32. Fisken RA, Heath DA, Bold AM: Hypercalcemia - A hospital survey. Q J Med 49:405-418, 1980
33. Coleman RE, Rubens RD: The clinical course of bone metastases from breast cancer. Br J Cancer 55:61-66, 1987
34. Ralston SH, Gallagher SJ, Parel U, et al: Cancer-associated hypercalcemia: Morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 112:499-504, 1990
35. Fitton A, McTavish D: Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289-318, 1991
36. Sauty A, Pecherstorfer M, Fioroni P, et al: Serum levels of TNF-α, IL-6 in patients treated with pamidronate, clodronate and BM 21.0955. Bone Mineral 25:69, 1994 (suppl 1; abstr 41).
37. Pecherstorfer M, Thiébaud D: Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD). Ann Oncol 3:661-663, 1992
38. Bounameaux HM, Schifferli J, Montani JP, et al: Renal failure associated with intravenous diphosphonate. Lancet 1:471, 1983
39. Francis MD, Slough C: Acute intravenous infusion of disodium dihydrogen (1-hydroxy-ethylidene) diphosphonate: Mechanism of cytotoxicity. J Pharmaceut Sci 73:1097-1100, 1983